| Robert Dale Niedringhaus, | |
|
400 E 3rd St, Duluth, MN 55805-1951 | |
| (218) 786-8364 | |
| Not Available |
| Full Name | Robert Dale Niedringhaus |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology |
| Location | 400 E 3rd St, Duluth, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013947993 | NPI | - | NPPES |
| 521085200 | Medicaid | MN | |
| 31287000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0000X | Internal Medicine - Hematology | 18665 (Minnesota) | Secondary |
| 207RH0000X | Internal Medicine - Hematology | 26690-20 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Dale Niedringhaus, 400 E 3rd St, Duluth, MN 55805-1951 Ph: (218) 786-8364 | Robert Dale Niedringhaus, 400 E 3rd St, Duluth, MN 55805-1951 Ph: (218) 786-8364 |
News Archive
For months, we have known that no plan will succeed if it just slashes programs such as Medicare or imposes big hikes in tax rates. We've known that we need a plan that eliminates at least $4 trillion in debt over the next decade, slows the growth in entitlement programs and raises new revenue through tax reform.
Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.
The Wistar Institute and collaborating institutions have received a major grant from the National Institutes of Health to further research on new melanoma targeted therapies integrating the role of the tumor microenvironment in influencing response to therapy and development of resistance.
A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
A research team at The University of Texas at El Paso is one step closer to developing an effective human vaccine for cutaneous leishmaniasis, a tropical disease found in Texas and Oklahoma, and affecting some U.S. troops stationed in Afghanistan and Iraq.
› Verified 7 days ago
Nizar Najib Saleh, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Dr. Joseph J Martinelli, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 920 E 1st St, Ste P201, Duluth, MN 55805 Phone: 218-249-7970 | |
Gina Marie Slipka-marinos, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Dr. Abdurrahman M Hamadah, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 E Superior St Ste L201, Duluth, MN 55802 Phone: 218-249-5555 | |
Sarah Jane Nelson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Thomas Edward Russ, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 |